Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Clinical trial NCT04266301 · TERMINATED
Trial details
- NCT number
- NCT04266301
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-08
- Primary completion
- 2024-10-02
- Enrollment
- 530
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.